Investigators will apply a new method to evaluate the activity of NK cells in pancreatic cancer patients, and to analyze the correlation with the progression of the tumor and the prognosis of the patient. And investigators will analyze the multifactorial factors affecting the activity of NK cells and conducted this study to help establish new diagnostic and therapeutic strategies for pancreatic cancer.
Age
20–80
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
The patient who is admitted to the pancreatic surgery department for the treatment of pancreas tumor
Patients must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up.
Life expectancy of at least 6 months based on discretion of treating
Adequate hematologic function defined by the following laboratory parameters: Hemoglobin \> 100, Platelet count \> 100 and Absolute granulocyte count \> 1.5.
You may not be if
Patients who received preoperative chemotherapy or radiotherapy.
Previous or concurrent malignancies.
Any serious medical condition within 6 months prior to study entry such as myocardial infarction, uncontrolled congestive heart failure, unstable angina, serous infection.
Clareo Health | Evaluation of Killing Activity of Expanded Natural Killer Cells From Blood in Patients With Pancreatic Cancer
